A citation-based method for searching scientific literature

Seng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, Jaishree Bankoti, Mark Selby, Christopher J Nirschl, Matthew L Bettini, David M Gravano, Peter Vogel, Chih Long Liu, Stephanie Tangsombatvisit, Joseph F Grosso, George Netto, Matthew P Smeltzer, Alcides Chaux, Paul J Utz, Creg J Workman, Drew M Pardoll, Alan J Korman, Charles G Drake, Dario A A Vignali. Cancer Res 2012
Times Cited: 939







List of co-cited articles
1405 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Jun Wang, Miguel F Sanmamed, Ila Datar, Tina Tianjiao Su, Lan Ji, Jingwei Sun, Ling Chen, Yusheng Chen, Gefeng Zhu, Weiwei Yin,[...]. Cell 2019
330
24

LAG3 (CD223) as a cancer immunotherapy target.
Lawrence P Andrews, Ariel E Marciscano, Charles G Drake, Dario A A Vignali. Immunol Rev 2017
411
22


Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Junko Matsuzaki, Sacha Gnjatic, Paulette Mhawech-Fauceglia, Amy Beck, Austin Miller, Takemasa Tsuji, Cheryl Eppolito, Feng Qian, Shashikant Lele, Protul Shrikant,[...]. Proc Natl Acad Sci U S A 2010
570
20

LAG-3, a novel lymphocyte activation gene closely related to CD4.
F Triebel, S Jitsukawa, E Baixeras, S Roman-Roman, C Genevee, E Viegas-Pequignot, T Hercend. J Exp Med 1990
477
19

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, Jenna M Sullivan, Bruce R Blazar, Vijay K Kuchroo, Ana C Anderson. J Exp Med 2010
18

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J Johnston, Laetitia Comps-Agrar, Jason Hackney, Xin Yu, Mahrukh Huseni, Yagai Yang, Summer Park, Vincent Javinal, Henry Chiu, Bryan Irving,[...]. Cancer Cell 2014
582
17

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J Gogas, Christopher D Lao, Juliana Janoski De Menezes,[...]. N Engl J Med 2022
112
16

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
15

LAG-3: from molecular functions to clinical applications.
Takumi Maruhashi, Daisuke Sugiura, Il-Mi Okazaki, Taku Okazaki. J Immunother Cancer 2020
86
17

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
15

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.
Theodore Kouo, Lanqing Huang, Alexandra B Pucsek, Minwei Cao, Sara Solt, Todd Armstrong, Elizabeth Jaffee. Cancer Immunol Res 2015
235
14

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
Joseph F Grosso, Cristin C Kelleher, Timothy J Harris, Charles H Maris, Edward L Hipkiss, Angelo De Marzo, Robert Anders, George Netto, Derese Getnet, Tullia C Bruno,[...]. J Clin Invest 2007
349
14

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Grit S Herter-Sprie, Kevin A Buczkowski, William G Richards, Leena Gandhi, Amanda J Redig, Scott J Rodig, Hajime Asahina,[...]. Nat Commun 2016
847
14

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Qing Zhang, Jiacheng Bi, Xiaodong Zheng, Yongyan Chen, Hua Wang, Wenyong Wu, Zhengguang Wang, Qiang Wu, Hui Peng, Haiming Wei,[...]. Nat Immunol 2018
462
13

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
13

Role of LAG-3 in regulatory T cells.
Ching-Tai Huang, Creg J Workman, Dallas Flies, Xiaoyu Pan, Aimee L Marson, Gang Zhou, Edward L Hipkiss, Sowmya Ravi, Jeanne Kowalski, Hyam I Levitsky,[...]. Immunity 2004
792
13

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Xin Yu, Kristin Harden, Lino C Gonzalez, Michelle Francesco, Eugene Chiang, Bryan Irving, Irene Tom, Sinisa Ivelja, Canio J Refino, Hilary Clark,[...]. Nat Immunol 2009
717
13

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
13

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
E Baixeras, B Huard, C Miossec, S Jitsukawa, M Martin, T Hercend, C Auffray, F Triebel, D Piatier-Tonneau. J Exp Med 1992
258
12

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
12

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
407
12


PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
11


LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.
Chiara Camisaschi, Chiara Casati, Francesca Rini, Michela Perego, Annamaria De Filippo, Frédéric Triebel, Giorgio Parmiani, Filiberto Belli, Licia Rivoltini, Chiara Castelli. J Immunol 2010
203
11

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J Korman,[...]. J Clin Invest 2015
423
11

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Yu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, Ana C Anderson, Amit Gandhi, Andrew Russell, Stephanie K Dougan, Britt-Sabina Petersen, Espen Melum, Thomas Pertel,[...]. Nature 2015
355
11

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, Aj Robert McGray, Anthony Miliotto, Kunle Odunsi. Oncoimmunology 2016
171
11

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Ruea-Yea Huang, Cheryl Eppolito, Shashikant Lele, Protul Shrikant, Junko Matsuzaki, Kunle Odunsi. Oncotarget 2015
162
11

LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.
Feng Xu, Jing Liu, Di Liu, Biao Liu, Min Wang, Zhiyuan Hu, Xuemei Du, Li Tang, Fuchu He. Cancer Res 2014
177
11

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
10

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.
Laurent Monney, Catherine A Sabatos, Jason L Gaglia, Akemi Ryu, Hanspeter Waldner, Tatyana Chernova, Stephen Manning, Edward A Greenfield, Anthony J Coyle, Raymond A Sobel,[...]. Nature 2002
10


T cell exhaustion.
E John Wherry. Nat Immunol 2011
10

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.
Shawn D Blackburn, Haina Shin, W Nicholas Haining, Tao Zou, Creg J Workman, Antonio Polley, Michael R Betts, Gordon J Freeman, Dario A A Vignali, E John Wherry. Nat Immunol 2009
10

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
Yayi He, Hui Yu, Leslie Rozeboom, Christopher J Rivard, Kim Ellison, Rafal Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou,[...]. J Thorac Oncol 2017
125
10

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
10

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
10

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
10

LAG-3 regulates plasmacytoid dendritic cell homeostasis.
Creg J Workman, Yao Wang, Karim C El Kasmi, Drew M Pardoll, Peter J Murray, Charles G Drake, Dario A A Vignali. J Immunol 2009
144
9

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Alice L Hung, Russell Maxwell, Debebe Theodros, Zineb Belcaid, Dimitrios Mathios, Andrew S Luksik, Eileen Kim, Adela Wu, Yuanxuan Xia, Tomas Garzon-Muvdi,[...]. Oncoimmunology 2018
148
9

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.
Chen Zhu, Ana C Anderson, Anna Schubart, Huabao Xiong, Jaime Imitola, Samia J Khoury, Xin Xiao Zheng, Terry B Strom, Vijay K Kuchroo. Nat Immunol 2005
9


Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison. Science 1996
9


Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
9

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
9

PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol 2008
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.